Appearance: white powder
Usage:On March 1,2011, the FDA approved the chronic obstructive pneumonia drug Daliresp (roflumilast), the drug used daily, can reduce asthma attack frequency or mitigate serious chronic obstructive pneumonia (COPD) symptoms.Roflumilast is a new category of COPD drug, phosphodiesterase - 4 (PDE - 4) inhibitors. Can be used among patients with serious COPD cough and bronchial symptom related much sputum, does not apply to mild emphysema.
Appearance : White or off white crystalline powder
Loss on drying : ≤0. 5%
Single impurity : ≤0.50%
Assay (HPLC) : ≥99.0%